Clinical and Genetic Profile of the ACTIVATE Population: A Phase 2 Trial of BIA 28-6156 in GBA-PD
Objective: To characterize the patient population enrolled in the ACTIVATE study, a Phase 2 multicenter, randomized, double-blind, placebo-controlled trial assessing the efficacy, safety, tolerability, pharmacodynamics,…Long-Term Open-Label Data on the GCase Modulator GT-02287 in People with Parkinson’s Disease
Objective: To evaluate the long-term safety, tolerability, and PK of the oral, brain-penetrant glucocerebrosidase (GCase) modulator GT-02287 in people with Parkinson’s disease. Background: Preclinical evidence…The ORCHESTRA Study Year 2: Practical Experiences With Foslevodopa/Foscarbidopa Treatment in Advanced Parkinson’s Disease in a Real-World Setting
Objective: To describe real-world learnings on the routine practical management of foslevodopa/foscarbidopa (LDp/CDp), a continuous 24-hour subcutaneous infusion therapy for advanced Parkinson’s disease (aPD), using…A case of monotherapy with intracerebroventricular anaerobic dopamine allows complete control of Parkinson’s disease symptoms
Objective: To investigate the safety and efficacy of continuous circadian and personalized intracerebroventricular (i.c.v.) administration of anaerobic dopamine (A-dopamine) in Parkinson's disease patients refractory to…Intranasal spray for nose-to-brain drug delivery: Emergency treatment of OFF episodes in Parkinson’s disease
Objective: To evaluate a novel nose-to-brain nasal spray (XJN010) for emergency treatment of OFF episodes in Parkinson's disease (PD) via clinical pharmacokinetics, safety, and tolerability.…Medical Management of Late-stage Parkinson’s Disease – a Cross-sectional, Multinational Survey
Objective: To investigate disease characteristics and common drug treatment of late-stage Parkinsons’ disease (LSPD). Background: LSPD presents with disabling motor and non-motor symptoms, the latter…How large must a Parkinson’s disease trial be to detect pharmacogenomic interactions? Power benchmarks derived from the Exenatide PD3 clinical trial
Objective: To investigate whether genetic variation in the GLP1R gene modifies treatment response to the GLP1 agonist exenatide in the Exenatide-PD3 trial, and to characterise…Translational evaluation of CSF as a relevant compartment for assessing target engagement of therapeutic anti–α-syn antibodies.
Objective: To evaluate a translational free/total α-synuclein (α-syn) assay framework to quantify in vivo target engagement (TE) of anti–α-syn antibodies in preclinical models and to…Continuous subcutaneous levodopa infusion in advanced Parkinson’s disease: a descriptive real-world cohort study
Objective: To describe clinical characteristics, treatment indications, safety profile, and treatment persistence in patients with advanced PD treated with continuous subcutaneous levodopa infusion. Background: Continuous…Real-world variability in dosing of continuous subcutaneous foslevodopa/foscarbidopa infusion in advanced Parkinson’s disease: evidence from a single-center cohort
Objective: To evaluate dosing patterns, demographic characteristics, and safety outcomes in patients with advanced Parkinson's Disease (PD) treated with continuous subcutaneous foslevodopa/foscarbidopa infusion in routine…
- 1
- 2
- 3
- …
- 36
- Next Page »